Nomura Holdings Inc. Has $3.25 Million Position in Vertex Pharmaceuticals Incorporated (VRTX)
Nomura Holdings Inc. increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 156.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 25,205 shares of the pharmaceutical company’s stock after acquiring an additional 15,366 shares during the quarter. Nomura Holdings Inc.’s holdings in Vertex Pharmaceuticals were worth $3,249,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Bank of Nova Scotia boosted its position in Vertex Pharmaceuticals by 104.5% during the second quarter. Bank of Nova Scotia now owns 116,259 shares of the pharmaceutical company’s stock worth $14,982,000 after acquiring an additional 59,397 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 27.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 6,469 shares of the pharmaceutical company’s stock valued at $834,000 after purchasing an additional 1,397 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 274,237 shares of the pharmaceutical company’s stock valued at $35,341,000 after purchasing an additional 3,271 shares during the last quarter. Redmile Group LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $18,610,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Vertex Pharmaceuticals by 647.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 31,839 shares of the pharmaceutical company’s stock valued at $4,103,000 after purchasing an additional 27,578 shares during the last quarter. Hedge funds and other institutional investors own 92.85% of the company’s stock.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up 0.023% on Friday, hitting $154.015. 230,004 shares of the stock traded hands. The stock has a 50-day moving average of $154.31 and a 200-day moving average of $135.39. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.86. The firm has a market cap of $38.83 billion, a price-to-earnings ratio of 147.949 and a beta of 1.73.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The company had revenue of $544.10 million during the quarter, compared to analysts’ expectations of $489.95 million. During the same quarter in the prior year, the company posted $0.24 EPS. The business’s revenue was up 26.1% on a year-over-year basis. Analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.62 earnings per share for the current year.
In other news, EVP Stuart A. Arbuckle sold 2,125 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $152.99, for a total value of $325,103.75. Following the sale, the executive vice president now owns 123,242 shares of the company’s stock, valued at approximately $18,854,793.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey M. Leiden sold 216,624 shares of the company’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $160.96, for a total transaction of $34,867,799.04. Following the completion of the sale, the chief executive officer now directly owns 400,266 shares in the company, valued at approximately $64,426,815.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 518,357 shares of company stock valued at $83,154,633. Corporate insiders own 1.80% of the company’s stock.
VRTX has been the topic of a number of research analyst reports. Cowen and Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price target on the stock in a report on Tuesday, September 26th. Jefferies Group LLC initiated coverage on shares of Vertex Pharmaceuticals in a report on Monday, July 10th. They issued a “buy” rating and a $155.00 price target on the stock. Credit Suisse Group lifted their price target on shares of Vertex Pharmaceuticals from $125.00 to $195.00 and gave the company an “outperform” rating in a report on Wednesday, July 19th. Finally, BidaskClub lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-three have given a buy rating and one has issued a strong buy rating to the stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $167.04.
TRADEMARK VIOLATION WARNING: “Nomura Holdings Inc. Has $3.25 Million Position in Vertex Pharmaceuticals Incorporated (VRTX)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/13/nomura-holdings-inc-has-3-25-million-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.